Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT04447573 is registered in ClinicalTrials.gov with Hebei Senlang Biotechnology Inc., Ltd. as lead sponsor.

NCT NCT04447573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04447573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
June 30, 2020
Completion date
December 30, 2022
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma